Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Aug 09, 2022 12:18pm
127 Views
Post# 34881922

RE:RE:RE:Getting rich or getting a return

RE:RE:RE:Getting rich or getting a return

As you know rabbits reproduce at a rapid pace!!!
Here are possible rabbits from the same hat
1- Dramatic increase in the sales volume of the legacy drugs combined with the added revenue from new distribution agreements or in licensing of drugs
2- Cash infusion by a Chinese partner ---a small rabbit but would improve confidence and of course the cash position
3- Good results in Phase 1b in at least one indication  which would pave the way for a Partnership agreement with a large pharma
4- Resolution of the F8 formulation which is a pre requisite for the initiation of the Nash trial with a Partner

SPCEO1 wrote: Can the same rabbit be pulled out of the hat twice? I hope so but am doubtful. It is unfortunate as the drug likely works in NASH but there must be something else going on that is preventing other drug companies from stepping up and pursuing it. I have specualted that it is a patent issue but it may just be the big drug companies do not trust the FDA as it is currently run to back a NASH solution. The rules surrounding getting a NASH approval, the need for biopsies, etc. may be the real issue keeping interest low in NASH. That being said, there has been some interest as indicated by t he twor ececnt deals between big pharma and smaller drug companies for NASH. 
 

palinc2000 wrote:

Not enough weight on Nash here imo...This could turn out to be the rabbit out of the hat 
 

 

palinc2000 wrote: I am staying  invested here because I have strong convictions that I will get a good return on what I have invested in THTX even if  TH-1902 turns out to be a dud ....If Thtx wins the Lottery with TH-1902 that would turn out to be fantastic returns 

I see that most(not all) here are only looking to get rich iin a very limited time period ...
These are 2 different investment thesis .... mine creates a lot less anxiety but I have no problem with those who have a different view  

 

 

 





<< Previous
Bullboard Posts
Next >>